 Kazia Therapeutics Ltd has received full regulatory approval for its planned phase 1 study for EVT801 from LAgence Nationale de Sécurité du Médicament et des Produits de Santé ANSM, the French regulatory agency. Kazia, an oncology-focused drug development company, licensed EVT801 from Evotec SE, an international drug discovery alliance and development partnership company, in April 2021. 